The 2001 Bethesda System: Terminology for Reporting Results of Cervical Cytology

Abstract

BACKGROUNDThe Bethesda System for reporting the results of cervical cytology was developed as a uniform system of terminology that would provide clear guidance for clinical management.

p16 staining has limited value in predicting the outcome of histological low-grade squamous intraepithelial lesions of the cervix

“…Cytology slides were evaluated by a cytotechnologist and reviewed by a pathologist using the revised Bethesda nomenclature. 23 hrHPV testing was performed in the cervical specimens collected in PreservCyt solution using the commercially available Hybrid Capture 2 (HC2) system (Qiagen, Gaithersburg, MD, USA). All the samples were analyzed for the presence of hrHPV types (16,18,31,33,35,39,45, 51, 52, 56, 58, 59, and 68).…”

“…A relative light units value of 1 (1.0 pg/ml) was used as the cutoff to classify and record each specimen as positive or negative. 23,24 The relative light units were recorded and used as a measure of viral load. 23,24 Histological Evaluation and Immunohistochemical Detection of p16…”

mRNA biomarker detection in liquid-based cytology: a new approach in the prevention of cervical cancer

“…Cytology slides were evaluated by a cytotechnologist and confirmed by a pathologist using the revised Bethesda nomenclature. 11 Subsequently, liquid-based cytology samples Formalin-fixed, paraffin-embedded 4-mm sections were routinely stained with hematoxylin and eosin (H&E). All the histological samples were reviewed by one of the authors (JO) to confirm the presence or absence of SIL and its grade.…”

Vaccines for cervical cancer

“…These include : redesigning cytology-based screening strategies in terms of age at which screening commences and frequency of screening ; introduction of thinlayer liquid-based cytology (LBC) to improve the performance (through improving smear quality and visibility) and sensitivity of cytology for detection of pre-cancerous lesions; and instituting a more conservative approach to the clinical management of low-grade cytological abnormalities [8]. Screening for high-risk HPV types in cervical samples, using DNA hybrid capture and nucleic acid amplification technology, is being explored for its utility both as a # In the recently introduced US Bethesda terminology system, these stages correspond to atypical squamous cells (ASC-US or ASC-H: cells which are abnormal but not frankly reactive or dysplastic); low-grade squamous intra-epithelial lesions (LGSIL; mild dysplasia and the changes associated with HPV infection, known as koilocytosis); and high-grade squamous intra-epithelial lesions (HGSIL; moderate and severe dysplasia, carcimona in situ) [34]. primary screening tool (particularly in women over 30 where HPV prevalence is lower), and as an adjunctive test in the management of women referred for abnormal cervical cytology [34,[45][46][47][48].…”

“…Screening for high-risk HPV types in cervical samples, using DNA hybrid capture and nucleic acid amplification technology, is being explored for its utility both as a # In the recently introduced US Bethesda terminology system, these stages correspond to atypical squamous cells (ASC-US or ASC-H: cells which are abnormal but not frankly reactive or dysplastic); low-grade squamous intra-epithelial lesions (LGSIL; mild dysplasia and the changes associated with HPV infection, known as koilocytosis); and high-grade squamous intra-epithelial lesions (HGSIL; moderate and severe dysplasia, carcimona in situ) [34]. primary screening tool (particularly in women over 30 where HPV prevalence is lower), and as an adjunctive test in the management of women referred for abnormal cervical cytology [34,[45][46][47][48]. Such approaches may decrease the numbers of women who undergo unnecessary aggressive treatment for low-grade cytological lesions identified through traditional Pap screening, and may improve detection rates of CIN 2+ without increasing the colposcopy referral rate.…”